Categories
Change Password!
Reset Password!
Human clinical trials to assess the effectiveness of
first-in-class α9α10 nicotinic acetylcholine receptor antagonist now approved.
As per an announcement by a clinical-stage biotechnology company on 12 August 2020 the Clinical Trial Application (CTA) has been approved in the Netherlands for initiation of a first-in-human clinical trial of KCP506 (first-in-class α9α10 nicotinic acetylcholine receptor (nAChR) antagonist) for chronic neuropathic pain treatment.
The safety and efficacy of KCP506 will be evaluated in
healthy individuals in this double-blind, placebo-controlled, single ascending
dose and multiple ascending dose study. The phase 1 clinical trials of KCP506
have been scheduled later in 2020. This regulatory approval marks a critical
milestone for this organization to evaluate the novel non-opioid in the clinic,
mentioned the company’s CEO. KCP506 has been believed to have the probability
of a disease-modifying therapy devoid of CNS side effects comprising addiction.
The α9α10 nAChR antagonists have confirmed its strong anti-neuroinflammatory,
pain-relieving potential and neuroprotective outcomes in many preclinical
models. KCP506 have the potential of easing chronic pain progression. Different
chronic neuropathic pain comprising of diabetic neuropathy, radiculopathy,
chemotherapy-induced peripheral neuropathy may benefit from KCP506.
This biotechnology company collaborated with a subsidiary
of Roche in April 2018 dedicated to developing first in class α9α10 nAChR
antagonists for chronic pain treatment.
CISION- PR Newswire
Kineta Receives Regulatory Approval for Initiation of Phase 1 Clinical Trials of KCP506
Comments (0)